Technical Analysis for NXTC - NextCure, Inc.

Grade Last Price % Change Price Change
F 9.42 -2.08% -0.20
NXTC closed down 2.08 percent on Monday, April 12, 2021, on 84 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical NXTC trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -2.08%
Wide Bands Range Expansion -2.08%
Oversold Stochastic Weakness -2.08%
Wide Bands Range Expansion -4.17%
Oversold Stochastic Weakness -4.17%
Multiple of Ten Bearish Other -3.29%
Older End-of-Day Signals for NXTC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 11 hours ago
Outside Day about 11 hours ago
Down 3% about 11 hours ago
Down 2 % about 11 hours ago
Down 1% about 11 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

NextCure, Inc. Description

NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Solid Tumors Immunotherapy Cancer Treatments Virotherapy Small Cell Lung Cancer Ovarian Cancer Non Small Cell Lung Cancer Tumor Related Disease Related Diseases Oncolytics Biotech Treatment Of Ovarian Cancer C3 Metastasis Halozyme Immune Related Diseases Metastatic Solid Tumors Tumor Microenvironment

Is NXTC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 39.77
52 Week Low 7.91
Average Volume 179,791
200-Day Moving Average 11.19
50-Day Moving Average 11.70
20-Day Moving Average 10.78
10-Day Moving Average 9.89
Average True Range 0.61
ADX 25.1
+DI 11.36
-DI 27.18
Chandelier Exit (Long, 3 ATRs ) 11.16
Chandelier Exit (Short, 3 ATRs ) 11.13
Upper Bollinger Band 12.86
Lower Bollinger Band 8.71
Percent B (%b) 0.17
BandWidth 38.50
MACD Line -0.62
MACD Signal Line -0.53
MACD Histogram -0.0905
Fundamentals Value
Market Cap 259.55 Million
Num Shares 27.6 Million
EPS -1.92
Price-to-Earnings (P/E) Ratio -4.91
Price-to-Sales 11.26
Price-to-Book 0.92
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.19
Resistance 3 (R3) 10.23 10.03 10.06
Resistance 2 (R2) 10.03 9.83 10.00 10.01
Resistance 1 (R1) 9.72 9.71 9.62 9.68 9.97
Pivot Point 9.52 9.52 9.47 9.49 9.52
Support 1 (S1) 9.21 9.32 9.11 9.17 8.87
Support 2 (S2) 9.01 9.20 8.98 8.83
Support 3 (S3) 8.70 9.01 8.78
Support 4 (S4) 8.66